How Cortical Implants Are Opening a New Era of Vision Restoration

Impossibile aggiungere al carrello

Puoi avere soltanto 50 titoli nel carrello per il checkout.

Riprova più tardi

Rimozione dalla Lista desideri non riuscita.

Riprova più tardi

Non è stato possibile aggiungere il titolo alla Libreria

Per favore riprova

Non è stato possibile seguire il Podcast

Per favore riprova

Esecuzione del comando Non seguire più non riuscita

How Cortical Implants Are Opening a New Era of Vision Restoration

Ascolta gratuitamente

Vedi i dettagli del titolo

For the millions of people living with severe vision loss or complete blindness, the clinical options available today remain extremely limited. Guide dogs, white canes and adaptive technologies are designed to work around a deficit rather than address it. In a medical landscape where cochlear implants have transformed outcomes for the hearing impaired, blindness has waited for a comparable breakthrough.That breakthrough may now be closer than most people realise. In this episode of Clinical Compass, Trisha Pillay speaks with Maarten Schelles, CTO and Co-Founder of ReVision, about the cortical brain implant his company has developed, a device that bypasses the damaged structures responsible for most blindness entirely and stimulates the visual cortex directly.Why Existing Solutions Leave Most Patients BehindTo understand what ReVision is attempting, it helps to understand why current approaches fall short. The majority of vision restoration devices on the market today are retinal implants, devices designed to stimulate remaining retinal tissue and send signals along the optic nerve to the brain. The problem is structural. These devices only work when functional retinal tissue is present and the optic nerve is intact. For patients whose blindness originates from optic nerve damage, advanced glaucoma, or extensive retinal degeneration, retinal stimulation offers nothing.Schelles puts the scale of this gap plainly. Approximately 90 to 95 per cent of blindness cases are caused by conditions affecting the optic nerve or retina in ways that render retinal stimulation ineffective. The devices that exist serve a minority of patients with very specific pathology. For everyone else, there is no equivalent innovation which is precisely the unmet need that drove the founding of ReVision.The Case for Targeting the Visual CortexThe cortical implant developed by ReVision takes a fundamentally different approach. Rather than attempting to restore the damaged pathway between the eye and the brain, the device bypasses that pathway altogether. Flexible electrode arrays are implanted directly onto the visual cortex, the region of the brain responsible for processing visual information and stimulate it directly to generate perception.There are several reasons why this approach holds significant clinical promise. The visual cortex is substantially larger than the retina, which means that far more electrodes can be implanted without interference between stimulation points. Greater electrode density translates to higher resolution perception. The cortical approach also removes the constraint of requiring any residual retinal or optic nerve function, broadening the eligible patient population considerably.The ideal candidates for this technology are individuals with no residual light perception due to conditions such as advanced glaucoma, retinal detachment, or diabetic retinopathy in its most advanced stages. Patients with intact visual cortex function but no viable pathway to transmit visual input are, in principle, candidates that no existing technology can currently serve. ReVision's device is designed specifically for them.There are, naturally, populations for whom the approach is not appropriate. Individuals with congenital blindness, in whom the visual cortex may not have developed the expected functional organisation, and patients with tumours or structural damage to the cortex itself are not candidates. Patient selection is therefore a central component of the clinical programme.Regulatory Milestones and the Path to Clinical EvidenceReVision has received FDA Breakthrough Device designation for its cortical implant, a regulatory milestone that carries practical significance beyond the recognition itself. The designation provides access to more frequent and structured engagement with the FDA during development, enabling earlier identification of potential issues and a more efficient pathway through the approval process. It also carries credibility with institutional investors and regulatory counterparts in Europe, where the company will eventually seek approval in parallel.The clinical trial programme is structured around staged objectives, beginning with safety. Before any claims about visual restoration can be made to a regulatory standard, the evidence base must establish that the device can be implanted and tolerated without unacceptable risk. The early phases of the trial are therefore designed to generate that safety data whilst also capturing preliminary signals of efficacy, the patterns of perception that implanted patients experience when the device is activated.Schelles is measured about what the trials can and cannot yet tell us. The full potential of the technology will only become clear as the clinical evidence accumulates. Early results from patients will shape decisions about electrode placement, stimulation parameters, and the rehabilitation protocols used to help patients interpret the signals the device...

Ancora nessuna recensione